Evidence map›Paper›PMID 40676182›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients.

Michael S Valic, Carl J Fisher, Mark Zheng, Alexander M Gregor, Wenlei Jiang, Conrad Chan, Harley H L Chan, Abdullah El-Sayes, Chris J Zhang, Tina Ye and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Michael S ValicPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Carl J FisherPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Mark ZhengPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Alexander M GregorPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Wenlei JiangPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Conrad ChanLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Harley H L ChanPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Abdullah El-SayesPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Chris J ZhangPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Tina YePrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Michael HalimPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Pamela SchimmerPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Celina LiPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Nicholas BernardsPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Arthur C K ChuLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Zhongli CaiLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Juan ChenPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Jonathan C IrishPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Kazuhiro YasufukuPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Robert WeersinkPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Raymond M ReillyPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Brian C WilsonPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada. gang.zheng@uhn.ca.ORCID 0000-0002-0705-7398

Funding

Ontario Institute for Cancer Research #P.CTP.698Terry Fox Research Institute #1075Terry Fox Research Institute #1137
6 · The paper itself

Abstract

purposePORPHYSOMES (PS) are multifunctional porphyrin-lipid nanoparticles for fluorescence-guided photochemical tumour ablation and immune stimulation. PS can be radiolabelled with Copper-64 (

methods

resultsKit prepared

conclusionsThe pharmacology and safety profiles of PS and

Indexed as

Copper RadioisotopesLipidsNanoparticlesNeoplasmsPorphyrinsRadiopharmaceuticalsAnimalsDogsHumansIsotope LabelingMaleRatsRats, Inbred F344Tissue DistributionCopper-64Copper RadioisotopesLipidsPorphyrinsRadiopharmaceuticalsNanoparticlesPharmacologyRadiation dosimetryRadiotracersToxicologyTranslational studies

Identifiers

PMID40676182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.